Biotechnology company Alchemab Therapeutics and Medicines Discovery Catapult (MDC) have received $2.06m (£1.7m) grant from Innovate UK to accelerate the development of disease modifying therapy to treat Huntington’s disease.
19 Dec 2022
16 Dec 2022
Biotechnology company Gilgamesh Pharmaceuticals has raised $39m in Series B financing round, led by Prime Movers Lab, for advancing treatments for mental health.
15 Dec 2022
Innovent Biologics and LG Chem Life Sciences have signed an agreement for the latter’s late-stage novel non-purine xanthine oxidase inhibitor (XOI) Tigulixostat for the chronic management of hyperuricemia in individuals with gout disease.
13 Dec 2022
Merck has initiated a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Imago BioSciences.
12 Dec 2022
Chinese company HitGen has signed a research agreement with biopharmaceutical firm Nitrase Therapeutics to discover DNA-encoded library-based drug.
02 Dec 2022
US-based biotechnology firm Rallybio has entered into a strategic alliance with AbCellera to discover, develop, and commercialise new antibody-based therapeutics for rare diseases.
01 Dec 2022
Gene editing company iECURE has raised $65m in a Series A-1 financing round to advance in vivo programmes to treat rare paediatric liver diseases.
11 Nov 2022
Harbour BioMed’s wholly owned subsidiary Nona Biosciences and global biotechnology firm ModernaTX have entered into a license and collaboration deal for the development of immunotherapies.
08 Nov 2022
Navrogen has signed a cooperative research and development agreement (CRADA) with the US National Cancer Institute (NCI) researchers for the clinical development of NAV-001.
07 Nov 2022
Amgen has reported positive end-of-treatment data from the Phase II OCEAN(a)-DOSE study of its investigational olpasiran (formerly AMG 890).